A Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Recruiting

• Conditions: Moderate to Severe Chronic Obstructive Pulmonary Disease; Respiratory - Chronic obstructive pulmonary disease

• Registration Number: ACTRN12610000345088
• Lead Sponsor: Schering-Plough

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-04-29
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Has a diagnosis of clinically stable COPD (indicated by no exacerbations or changes in treatment within 6 weeks of screening.
2. Has a history for 3 months or more of sputum production most days of week.
3. Must be an ex-smoker with at least 6-months smoking cessation or a current smker with a smoking history of 10 or more pack-years.

Exclusion Criteria

1. Has been diagnosed with asthma or other clinically relevant lung disease.
2. Has undergone a lobectomy, pneumonectomy, lung volume reduction or other lung surgery.
3. Needs supplemental oxygen therapy for more than 12 hours per day.
4. A low white cell count at the screening visit.
5. Subjects using medication that may interfere with the effect of the study medication or has a clinically relevant medical condition that interferes with study procedures/evaluations or any condition that is determined to be significant by the principal investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified